Our history

Gerot Lannach was formed out of a merger of the two pharmaceutical companies Gerot and Lannacher and has a history of more than 70 years.

We develop and manufacture both branded and complex generic medicines to help healthcare professionals across the world manage a broad range of conditions.

Gerot Lannach UK was established in 2021 to support the NHS in providing high quality healthcare to its patients in the most affordable way.

Martin Bartenstein
CEO
Ilse Bartenstein
CEO
    Martin Bartenstein
    CEO
    Ilse Bartenstein
    CEO
1947/48
Foundation of Lannacher Heilmittel in Lannach/Graz and Gerot Pharmazeutika in Vienna
1966
Leopold and Hannelore Bartenstein take over Lannacher Heilmittel
1997
Lannacher Heilmittel acquires Gerot Pharmazeutika
2003
Start of operation in the state-of-the-art solid forms production site Lannach
2009
Lannacher and Gerot merge under the brand Gerot Lannach in G.L. Pharma
2021
Formation of Gerot Lannach UK located on the outskirts of the Cambridge life sciences cluster
    1947/48
    Foundation of Lannacher Heilmittel in Lannach/Graz and Gerot Pharmazeutika in Vienna
    1966
    Leopold and Hannelore Bartenstein take over Lannacher Heilmittel
    1997
    Lannacher Heilmittel acquires Gerot Pharmazeutika
    2003
    Start of operation in the state-of-the-art solid forms production site Lannach
    2009
    Lannacher and Gerot merge under the brand Gerot Lannach in G.L. Pharma
    2021
    Formation of Gerot Lannach UK located on the outskirts of the Cambridge life sciences cluster
Facts & Figures

Markets
Our products can be found in more than 50 markets worldwide. Gerot Lannach has 16 distribution structures in Europe and a subsidiary in Central America.

Headcount
~1.000 employees

Revenues
~€220 M. (2021) revenue, €320 M. (2021) including Genericon Pharma

Production Volume
~4.400 M. single doses

 
Facts & Figures

Markets
Our products can be found in more than 50 markets worldwide. Gerot Lannach has 16 distribution structures in Europe and a subsidiary in Central America.

Headcount
~1.000 employees

Revenues
~€220 M. (2021) revenue, €320 M. (2021) including Genericon Pharma

Production Volume
~4.400 M. single doses

Transparency

Gerot Lannach works closely with healthcare professionals and medical facilities to provide optimum patient care, an area where we believe that trust and transparency should come as standard.

As part of our ongoing commitment for transparency, we fully support the disclosure provisions of EFPIA and PMCPA.